- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.02. | Proposed Delisting via Merger of BenevolentAI into Osaka Holdings S.à r.l. and Publication of Notice of Extraordinary General Meeting | 458 | Business Wire | Regulatory News:
BenevolentAI, ("BenevolentAI" or "the Company") (Euronext Amsterdam: BAI), a pioneer in AI-driven drug discovery, today announces:
Subject to shareholder approval, the proposed... ► Artikel lesen | |
| 11.12.24 | AI Biotech BenevolentAI Restructures Again, This Time to Return to Its TechBio Roots | 11 | MedCity News | ||
| 11.12.24 | BenevolentAI restructures; Lilly preps $15B buyback program | 10 | BioPharma Dive | ||
| BENEVOLENTAI Aktie jetzt für 0€ handeln | |||||
| 11.12.24 | Mulvany hits the reset button at BenevolentAI | 12 | pharmaphorum | ||
| 11.12.24 | BenevolentAI pivots back to 'TechBio' roots, causing more layoffs | 11 | FierceBiotech | ||
| 11.12.24 | BenevolentAI Unveils Major Strategic Overhaul With Return to Original Mission | 295 | Business Wire | Changes mark a return to BenevolentAI's foundational strengths Initiates significant organisational restructuring Announces intention to evaluate delisting from Euronext Amsterdam
Regulatory... ► Artikel lesen | |
| 18.10.24 | Chutes & Ladders-Less than a year in, BenevolentAI CEO is out | 17 | FierceBiotech | ||
| 18.10.24 | BenevolentAI CEO steps down as founders make a comeback | 12 | pharmaphorum | ||
| 17.10.24 | BenevolentAI Appoints Kenneth Mulvany as Executive Chairman | 239 | Business Wire | Founder of leading AI drug discovery company returns to the executive management team to capitalise on the growing adoption of AI in drug discovery and development
BenevolentAI ("BenevolentAI"... ► Artikel lesen | |
| 10.10.24 | BenevolentAI to Present on Explainable AI for Drug Discovery at BioTechX Europe 2024 | 286 | Business Wire | BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces that Dr James Malone, Chief Technology... ► Artikel lesen | |
| 19.09.24 | BenevolentAI Interim Results for the Six Months Ended 30 June 2024 | 367 | Business Wire | Strengthened Executive Leadership and Board Positive Top Line Phase I Data Reported for BEN-8744, Full Data to be Presented at Upcoming Leading Medical Conference Advancements in Target Identification... ► Artikel lesen | |
| 06.09.24 | BenevolentAI Notice of Interim Results | 363 | Business Wire | BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, will announce its interim results for the six months... ► Artikel lesen | |
| 04.07.24 | BenevolentAI: Appointment of Adviser | 363 | Business Wire | BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the... ► Artikel lesen | |
| 03.07.24 | BenevolentAI: Leadership Team Change | 413 | Business Wire | Regulatory News:
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced artificial intelligence (AI) to accelerate biopharma drug discovery, today... ► Artikel lesen | |
| 25.06.24 | BenevolentAI and AstraZeneca Collaboration Yields Continued Success as Further Novel Target Progressed Into Portfolio | 850 | Business Wire | BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces that AstraZeneca has added a novel target... ► Artikel lesen | |
| 19.06.24 | BenevolentAI CEO to Join Panel at Morgan Stanley 3rd Annual Life Sciences AI Summit | 359 | Business Wire | BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces that it will participate in the upcoming... ► Artikel lesen | |
| 04.06.24 | BenevolentAI to participate in Goldman Sachs 45th Annual Global Healthcare Conference | 326 | Business Wire | BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces that it will participate in the upcoming... ► Artikel lesen | |
| 15.05.24 | BenevolentAI Announces Further Success With AstraZeneca Collaboration as Novel Heart Failure Target Selected | 762 | Business Wire | BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces that AstraZeneca has added a novel target... ► Artikel lesen | |
| 02.05.24 | BenevolentAI: Result of Annual General Meeting | 317 | Business Wire | Regulatory News:
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery announces that all resolutions... ► Artikel lesen | |
| 23.04.24 | BenevolentAI Provides an Update on Its Business Priorities | 518 | Business Wire | Regulatory News:
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces an update on... ► Artikel lesen |
Seite:
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CUREVAC | 2,954 | -1,14 % | Überflieger 2025: Valneva, BioNTech oder CureVac? | Biotech-Aktien von Valneva, BioNTech oder Curevac konnten nach langen Durstsrecken in den letzten Monaten wieder Momentum generieren und neue Anleger gewinnen. Allen voran der französische Impfstoffentwickler... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 6,590 | 0,00 % | Recursion Pharmaceuticals: Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results | Reported promising safety and preliminary efficacy data for REC-617, an oral CDK7 inhibitor, and met primary endpoints and demonstrated encouraging trends in efficacy for REC-994 in cerebral cavernous... ► Artikel lesen | |
| ABCELLERA BIOLOGICS | 2,309 | -7,34 % | Benchmark maintains Hold on AbCellera stock, no price target change | ||
| OXFORD NANOPORE TECHNOLOGIES | 1,282 | -6,97 % | Oxford Nanopore Tech - Issue of Equity and Total Voting Rights | ||
| ANAVEX LIFE SCIENCES | 8,098 | +6,05 % | Anavex Life Sciences (NASDAQ:AVXL) Trading 5.6% Higher - Here's What Happened | ||
| VERACYTE | 33,600 | 0,00 % | VERACYTE, INC. - 10-K, Annual Report | ||
| ASCLETIS PHARMA | 0,915 | +12,96 % | Ascletis Pharma Reports Positive Interim Phase 1b Data For ASC30 To Treat Obesity | BEIJING (dpa-AFX) - Ascletis Pharma Inc. (ASCLF.PK) Wednesday reported positive interim results from the Phase 1b study of ASC30 for the treatment of obesity.The Phase Ib multiple ascending... ► Artikel lesen | |
| BIOMEA FUSION | 2,645 | 0,00 % | Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) | REDWOOD CITY, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea") (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that on March 3, 2025... ► Artikel lesen | |
| JASPER THERAPEUTICS | 5,600 | 0,00 % | Oppenheimer maintains $80 target on Jasper Therapeutics stock | ||
| RELAY THERAPEUTICS | 3,205 | 0,00 % | Relay Therapeutics stock target cut to $12 at Citizens JMP | ||
| ABSCI | 3,415 | 0,00 % | Why Absci Corporation (ABSI) is Skyrocketing So Far in 2025 | ||
| LANTERN PHARMA | 3,900 | 0,00 % | Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates | DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence ("AI") company developing targeted and transformative cancer therapies using its proprietary RADR® AI and... ► Artikel lesen | |
| Y-MABS THERAPEUTICS | 5,175 | 0,00 % | Y-mAbs Therapeutics, Inc.: Y-mAbs Announces Publication of Phase 2 Interim Results in Nature Communications | NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization... ► Artikel lesen | |
| QIAGEN | 36,890 | +0,16 % | Qiagen NV-Aktie kann Vortagsniveau nicht halten (37,31 €) | Im Minus liegt zur Stunde die Aktie von Qiagen NV . Der jüngste Kurs betrug 37,31 Euro. Für das Wertpapier von Qiagen NV steht gegenwärtig ein Verlust von 1,39 Prozent zu Buche. Die Aktie verbilligte... ► Artikel lesen | |
| EVOTEC | 8,150 | -0,43 % | Kurs von Evotec steigt etwas (8,85 €) | Die Evotec-Aktie notiert heute fester. Das Papier kostete zuletzt 8,85 Euro. Am Aktienmarkt liegt die Evotec-Aktie zur Stunde im Plus. Die Aktie legte um 33 Cent zu. Aktuell wird das Wertpapier an der... ► Artikel lesen |
BENEVOLENTAI gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,003 (-1,99 %) liegt der Kurs bei 0,123 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BENEVOLENTAI finden Sie auf Wallstreet Online.
